Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Investor Presentation (January 2026)
31 slides from Invivyd's investor presentation, Jan 8, 2026
Slide 1: Invivyd Corporate Deck January 2026
Exhibit 99.2 Invivyd Corporate Deck January 2026 © 2026 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners. 1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words
Slide 3: Agenda
01 Invivyd Approach 02 COVID 03 Long COVID agenda 04 RSV 05 Financial Highlights 3
Slide 4: Developing potential best-in-class antibody therapies across multiple viral threats
We’re developing potential best- in-class antibody therapies across The need multiple viral threats, providing protection and defining what’s next in keeping people well. With is urgent. a broad pipeline and sharp execution, we’re moving quickly to turn breakthrough science into lasting impact and v
Slide 5: A Bespoke Platform For ID mAb Discovery
A Bespoke Platform For ID mAb Discovery Proprietary Analytics Best-in-Class mAbs Discovery Platform Mutable Targets 5
Slide 6: The Right Technology Designed to Address Major Needs Beyond COVID
The Right Technology Designed to Address Major Needs Beyond COVID COVID RSV Long Half-Life / Measles Prevention of Tick-borne (Lyme, etc.)* Disease / Vaccine Alternatives Pediatric Bridge to Immunologic Maturity (Mumps, Rubella, Diptheria, Pertussis)* COVID RSV Short Half-Life / Measles Treatment of
Slide 7: Agenda
01 Invivyd Approach 02 COVID 03 Long COVID agenda 04 RSV 05 Financial Highlights 7
Slide 8: SARS-CoV-2 compared with influenza and RSV
Perceived as Influenza RSV a “respiratory” Entry via sialic acid receptor Entry via CX3CR1 Largely bronchoepithelial cells Largely bronchoepithelial cells virus because of transmission, but actually a vascular, prothrombotic, SARS-CoV-2 immunomodulatory Entry via ACE2 Epithelial and endothelial cell
Slide 9: COVID's systemic complications continue to unfold
COVID’s systemic complications continue to unfold All trademarks and logos displayed are the property of their respective owners. Their use here is for identification purposes only and does not constitute endorsement or affiliation. 9
Slide 10: Reasons Americans avoided COVID vaccine
Only 12.9% of Americans say the main reason they have avoided getting a COVID vaccine in the ‘24 season was because they weren’t worried about getting infected. 10 Source: Centers for Disease Control and Prevention, Reasons for non-vaccination with COVID-19, influenza, and RSV vaccines during the 20
Slide 11: The current solution is the problem
The current solution is the problem When asked to select all reasons for not getting a COVID or FLU vaccine, respectively, respondents noted the main reason for not getting vaccinated as follows: COVID Vaccine FLU Vaccine Don’t trust government Other 6.7% 5.7% No time/ did not Vaccine can’t 8.8% 5.8
Slide 12: The Clinical Data: vaccine efficacy follow-up and labels
The Clinical Data Phase 3 RCTs: ~2 months of efficacy follow-up Current Disconnected The FDA Labels state of COVID “Once – OR – More than 2 months since last boost dose” mRNA vaccine prevention Observed Utilization Annual booster Sources: (1) Vaccines and Related Biological Products Advisory Committ
Slide 13: COVID demands monoclonal antibodies
COVID In contrast to vaccines, demands monoclonal antibodies can be engineered for monoclonal consistent high activity antibodies 13 13
Slide 14: We innovate to stay ahead
We innovate to stay ahead Minimally evolved molecular and seek to engineered [MEME] improve performance pemivibart VYD2311 Humans have limited antibody diversity and capability. Invivyd innovation has no such limit. 14
Slide 15: Robust durability and stability of our antibodies
We have seen robust durability and stability of our antibodies Engineered against stable epitopes – beyond human immune capability 15
Slide 16: PEMGARDA is helping establish long-term commercial foundation
PEMGARDA is helping establish Invivyd’s long-term commercial foundation Preliminary PEMGARDA Established Strong Commercial Foundation $17.2M* Net Product Revenue Q4 ’25 In-line commercial team and Continued sales growth QoQ in infrastructure to support long-term 2025 growth Building from Specialty I
Slide 17: Broad recognition from societies and guidelines for antibodies in COVID
Broad recognition from Societies and Guidelines for Antibodies in COVID SOCIETY / GUIDELINE PEMGARDA OR MAB TARGET AUDIENCE HIV.gov PEMGARDA Immunodeficiency IDSA Pemivibart Infectious disease NCCN – B-Cell Lymphomas Pemivibart Oncology NCCN – Infection Prevention Pemivibart Oncology Immune Deficien
Slide 18: COVID Vaccines: Big Revenue, Small Protection
COVID Vaccines: Big Revenue, Small Protection 18 and over vaccine efficacy (VE) reduction in hospitalization estimate from CDC 2023–2024 vaccine dose, ≥7 days 36% $3.8B 7–59 days earlier 51% (45–56) FY24 60–119 days earlier 42% (35–48) U.S. Revenue 120–179 days earlier 15% (3–26) Source: FDA. Effect
Slide 19: Tailwinds for VYD2311
1 mRNA risk/benefit concerns 1 Current Unique non-vaccine MOA with potential to prevent COVID 2 provides a competitive and compelling differentiator market offers Significant unmet need for vaccine alternatives 3 tailwinds for 2 Total addressable market is significant VYD2311 4 Growing identificatio
Slide 20: Strategies and Tactics to increase Awareness, Education, and Activation
Strategies and Tactics designed to increase Awareness, Education, and Activation* Expansion of sales force 1 Scale existing commercial efforts Education of healthcare providers beyond specialty 2 medicine, with focus to include primary care for VYD2311, Move toward more vaccine-like distribution and
Slide 21: VYD2311/REVOLUTION Clinical Program
VYD2311/REVOLUTION Clinical Program Pivotal Efficacy Study Vaccine Study Phase 1/2 Study ‘DECLARATION’ Phase 3, Randomized, double-blind, placebo- ‘LIBERTY’ Safety/Tolerability placebo-controlled efficacy controlled trial was conducted to evaluate comparison with COVID trial in prevention of safety,
Slide 22: Study designs for DECLARATION and LIBERTY
Day 90 Day 1 Day 30 Day 60 End of Study 60-Day Treatment Period 30-Day Follow-up Period VYD2311 Placebo Placebo VYD2311-SD (single dose) R VYD2311 VYD2311 VYD2311 VYD2311-MD Screening 1:1:1 (multidose) (up to Day -14) N1770 Placebo Placebo Placebo Placebo Monitor for CLI symptoms: Day 1 to Day 90 If
Slide 23: Repeat dose data
Repeat dose Why study safety and titer VYD2311 in multi-doses? data Anticipate that, if approved, most people would choose to get VYD2311 once a year, with a safety profile that enables extra protection for those who want it.* 23 *Depending on Prescribing Information, if approved
Slide 24: Building a category to serve humanity where they are today
Building a category to serve humanity where they are today Consumers HCPs Belief that COVID needs to be Belief that COVID needs to be avoided avoided Trust in Safety and Efficacy Trust in Efficacy and Safety Easy access and availability Easy access and availability CP Broad awareness ACIP and Societ
Slide 25: Agenda
01 Invivyd Approach 02 COVID 03 Long COVID agenda 04 RSV 05 Financial Highlights 25
Slide 26: SPEAR Group
SPEAR Group Invivyd and leading researchers have formed the SPEAR (Spike Protein Elimination and Recovery) Study Group to assess the effects of mAb therapy for Long COVID and COVID- 19 Post-Vaccination Syndrome. Key elements of a proposed clinical study to evaluate the effects of mAb therapy on Long
Slide 27: Agenda
01 Invivyd Approach 02 COVID 03 Long COVID agenda 04 RSV 05 Financial Highlights 27
Slide 28: Potential best-in-class RSV antibody candidate
Potential best-in-class RSV antibody candidate Pediatric RSV prophylaxis is a blockbuster market expected to grow to $3-$4B in annual revenues globally by 2030. VBY329 is designed for the prevention of RSV infections in newborns, infants, and children and for higher potency and improved barrier to r
Slide 29: Agenda
01 Invivyd Approach 02 COVID 03 Long COVID agenda 04 RSV 05 Financial Highlights 29
Slide 30: Financial Highlights
Financial Highlights Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million* • 25% growth over Q4 2024 • 31% growth over Q3 2025 Preliminary December 2025 ending cash and cash equivalents of $226.7 million*; secured over $200 million of capital in 2H 2025 PEMGARDA® Net Produ
Slide 31: Invivyd is leading change and shaping the future
Invivyd is leading change and shaping the future Move away from: Enable shift in American / • COVID vaccine-only approach to prevention global infectious disease • Central / paternal public health posture (mandate) prevention that any perspective • Limitation imposed by human immune systems or polit